Ferring Position on Alabama Supreme Court Ruling in LePage v Mobile Infirmary Clinic
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility…
// //
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility…
Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium…
Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy…
Ferring Pharmaceuticals’ Fertility Out Loud Docuseries follows four U.S.-based couples as they face their unique fertility journeys head-on Episode one…
36-month follow-up data from the Phase 3 study demonstrate one-quarter of patients with high-risk, BCG-unresponsive NMIBC remained free of high-grade…
Parsippany, NJ – November 15, 2023 – Ferring Pharmaceuticals appreciates the ongoing support from New Jersey and Minnesota as both…
New analysis evaluates the association between gut microbiome composition and health-related quality of life for patients with recurrent C. diff…
“Transformational” Gift will Establish the “Ferring Endowment for the Education of Healthcare Professionals in Training” Washington, DC and Parsippany, NJ…
Analysis looks at early experience with REBYOTA in clinical practice Additional analyses evaluate efficacy and safety of REBYOTA in patients…
Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal…